Press Releases

News from Opus Genetics

New Preliminary Clinical Data on Potential of Opus AAV-based Gene Therapy for Rare Inherited Retinal Disease to be Presented at the American Academy of Ophthalmology Annual Conference 2023
Data to be presented as part of gene augmentation therapy presentation  » Full Release
Opus Genetics Announces First Patient Dosed in Phase 1/2 Trial of Gene Therapy OPGx-LCA5 in Patients with Rare Inherited Retinal Disease LCA5
OPGx-LCA5 is designed to address vision loss due to Leber congenital amaurosis associated with mutations in the LCA5 gene, which causes one of the most severe early-onset retinal dystrophies » Full Release
Opus Genetics Announces New Data Highlighting Potential of AAV-based Gene Therapy for RDH12- and MERTK-associated Retinal Dystrophies
Detectable photoreceptors and signaling activity in patients with RDH12-associated Leber congenital amaurosis support potential of functional restoration by targeted gene therapy » Full Release
Opus Genetics Announces Upcoming Presentations on AAV-based Gene Therapy Programs for Inherited Retinal Diseases
Oral presentation on BEST1 clinical translation to be delivered during the 8th Annual Retinal Cell and Gene Therapy Innovation Summit Two posters related to RDH12 and MERTK programs to be presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2023 » Full Release
Opus Genetics Leadership to Present at Biotech Showcase™ 2023
Opus Genetics will present a company overview and provide an update on Opus’ gene therapy programs for inherited retinal diseases at the Biotech Showcase™ 2023 in San Francisco. » Full Release
Opus Genetics Announces Acquisition of the Rights to Two Gene Therapy Product Candidates for Inherited Retinal Diseases
Opus to advance preclinical development programs for BEST1- and RHO-related retinal diseases » Full Release
Opus Genetics Receives FDA Clearance of IND Application for OPGx-001, a Gene Therapy Candidate Intended for the Treatment of Rare Inherited Retinal Disease LCA5
OPGx-001 is Opus’ first program to enter clinical evaluation and is designed to address vision loss due to mutations in the LCA5 gene, which causes one of the most severe forms of early-onset blinding disease Leber congenital amaurosis » Full Release
Opus Genetics Leadership to Present at BTIG Ophthalmology Day
Opus Genetics, a patient-first gene therapy company developing treatments for inherited retinal diseases, today announced that Ben Yerxa, Ph.D., Chief Executive Officer of Opus, will participate in a fireside chat during the virtual BTIG Ophthalmology Day on Tuesday, November 29, 2022, at 2:30 p.m. ET. » Full Release
Opus Genetics Sponsors Uni-Rare Natural History Study for People with Inherited Retinal Diseases
Opus Genetics, a patient-first gene therapy company developing treatments for inherited retinal diseases, today announced the company will co- sponsor the Uni-Rare Study, a new natural history study for approximately 1,500 people with mutations in one of more than 300 rare genes associated with inherited retinal diseases (IRDs). » Full Release
Opus Genetics Expands Board of Directors with Appointment of Global Ophthalmology Leader Dr. Adrienne Graves
Opus Genetics, a patient-first gene therapy company developing treatments for inherited retinal diseases, today announced the appointment of Adrienne Graves, Ph.D., to its board of directors. » Full Release
Opus Genetics Leadership to Present at 3rd Annual Gene Therapy for Ophthalmic Disorders Conference
Research Triangle Park, N.C. – September 12, 2022 – Opus Genetics, a patient-first gene therapy company developing treatments for inherited retinal diseases, today announced that ... » Full Release
Opus Genetics Hosts Inaugural Patient Advocacy Outreach Webinar on Inherited Retinal Diseases
Virtual event details Opus’ unique and transparent approach to building company centered on patient need, provides update on lead programs in Leber congenital amaurosis Research ... » Full Release
Opus Genetics Expands its Leadership Team
Research Triangle Park, N.C. – July 21, 2022 – Opus Genetics, a patient-first gene therapy company developing treatments for inherited retinal diseases, today announced the appointments of Vikram Arora, Ph.D., DABT, as Vice President of Non-Clinical Development; Erin O’Neil, M.D., as Vice President of Clinical Development; and Sarah Tuller, J.D., RAC, as Vice President of Regulatory Affairs and Medical Writing. » Full Release
Opus Genetics to Present at OIS Retina Innovation Summit 2022
Ben Yerxa, Ph.D., president and CEO of Opus, will present at the Ophthalmology Innovation Source (OIS) Retina Innovation Summit 2022 on Wednesday, July 13, 2022, in New York. » Full Release
Opus Genetics Appoints Ben Yerxa, Ph.D., as Permanent Chief Executive Officer
Industry veteran and experienced CEO will continue to lead the company as its AAV-based gene therapies for inherited retinal diseases approach the clinic » Full Release
Opus Genetics Appoints Jennifer Hunt Chief Development Officer
Biopharma clinical development veteran to propel Opus’ AAV-based gene therapies for inherited retinal diseases toward patients » Full Release
Opus Genetics Announces Promising New Data Highlighting Potential of AAV-based Gene Therapies for the Treatment of Rare Inherited Retinal Diseases
Retinal regions of preserved photoreceptors identified as targets for subretinal delivery of AAV8-based gene therapy to address mutations in genes that cause forms of Leber congenital amaurosis » Full Release
New Data on Potential of Opus AAV-based Gene Therapies for Rare Inherited Retinal Diseases to be Presented at Association for Research in Vision and Ophthalmology Annual Meeting 2022
Data support the continued development of OPGx-001 and OPGx-002 to address mutations in genes causing forms of Leber congenital amaurosis » Full Release
Opus Enters Strategic Collaboration with Resilience for AAV-based Gene Therapy Development and Manufacturing for Inherited Retinal Diseases
 Opus’ first-in-human trials to begin in 2022 » Full Release
Opus Genetics Appoints Brian Leising Vice President, Manufacturing
20-year biopharma industry veteran to lead manufacturing for Opus’ AAV-based gene therapies for inherited retinal diseases RALEIGH, N.C., Feb. 15, 2022 (GLOBE NEWSWIRE) — Opus ... » Full Release
Opus Genetics Announces Agreement with Massachusetts Eye and Ear and Harvard Medical School to License Third Program for Inherited Retinal Disease
Program targets NMNAT1 gene based on the work of Opus scientific founder Dr. Eric Pierce RALEIGH, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) — Opus Genetics, ... » Full Release
Opus Genetics Announces Presence at Eyecelerator@AAO 2021
ALEIGH, N.C., Nov. 08, 2021 (GLOBE NEWSWIRE) — Opus Genetics, a patient-focused gene therapy company developing treatments for orphan inherited retinal diseases, today announced that ... » Full Release
Opus Genetics Announces Two Key Leadership Appointments
Dr. Ash Jayagopal named Chief Scientific Officer Mr. Joe Schachle appointed Chief Operating Officer RALEIGH, N.C., Oct. 20, 2021 (GLOBE NEWSWIRE) — Opus Genetics, a ... » Full Release
RD Fund Launches Opus Genetics with $19M Seed Funding to Advance Gene Therapy Treatments for Blinding Conditions
Initial programs will focus on treatments for rare pediatric blinding conditions Company formed to advance the work of scientific cofounders Dr. Jean Bennett, Junwei Sun ... » Full Release